TY - JOUR
T1 - Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region
AU - Castellsagué, Xavier
AU - Ault, Kevin A.
AU - Bosch, F. Xavier
AU - Brown, Darron
AU - Cuzick, Jack
AU - Ferris, Daron G.
AU - Joura, Elmar A.
AU - Garland, Suzanne M.
AU - Giuliano, Anna R.
AU - Hernandez-Avila, Mauricio
AU - Huh, Warner
AU - Iversen, Ole Erik
AU - Kjaer, Susanne K.
AU - Luna, Joaquin
AU - Monsonego, Joseph
AU - Muñoz, Nubia
AU - Myers, Evan
AU - Paavonen, Jorma
AU - Pitisuttihum, Punnee
AU - Steben, Marc
AU - Wheeler, Cosette M.
AU - Perez, Gonzalo
AU - Saah, Alfred
AU - Luxembourg, Alain
AU - Sings, Heather L.
AU - Velicer, Christine
N1 - Funding Information:
Xavier Castellsagué reports having received institutional research grants from Merck and Co., Inc., Sanofi Pasteur MSD, GlaxoSmithKline, and Genticel, and occasional personal travel grant and speakers honorarium from Sanofi Pasteur MSD and Vianex
Funding Information:
Kevin A. Ault reports having received grants to his institution from Merck and the National Institutes of Health and advisory committee fees from the American College of Obstetricians and Gynecologists. He also serves on the editorial board for the National Cancer Institute (USA).
Funding Information:
This study was funded by Merck and Co., Inc. , Kenilworth, NJ (ClinicalTrials.gov: NCT00092521 , NCT00092534 , and NCT00090220 ). This systematic review was designed, managed, and analyzed jointly by authors employed by Merck & Co. and external authors who were not paid for their work.
Funding Information:
Susanne K. Kjaer reports having received scientific advisory board and speaker׳s fees and unrestricted research grants through her institution from Sanofi Pasteur MSD and Merck, and scientific advisory board fee from Roche.
Publisher Copyright:
© 2016 The Authors.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Background: We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to 14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/52/58) vaccine types, by region. Methods: Women ages 15-26 and 24-45 years from 5 regions were enrolled in qHPV vaccine clinical trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS) cases were diagnosed by pathology panel consensus. Results: Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation was observed in 9vHPV type prevalence in CIN1 (~50%) and CIN2/3 (81-85%). Types 31/33/45/52/58 accounted for 25-30% of CIN1 in Latin America and Europe, but 14-18% in North America and Asia. Types 31/33/45/52/58 accounted for 33-38% of CIN2/3 in Latin America (younger women), Europe, and Asia, but 17-18% of CIN2/3 in Latin America (older women) and North America. Non-vaccine HPV types 35/39/51/56/59 had similar or higher prevalence than qHPV types in CIN1 and were attributed to 2-11% of CIN2/3. Conclusions: The 9vHPV vaccine could potentially prevent the majority of CIN1-3, irrespective of geographic region. Notwithstanding, non-vaccine types 35/39/51/56/59 may still be responsible for some CIN1, and to a lesser extent CIN2/3.
AB - Background: We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to 14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/52/58) vaccine types, by region. Methods: Women ages 15-26 and 24-45 years from 5 regions were enrolled in qHPV vaccine clinical trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS) cases were diagnosed by pathology panel consensus. Results: Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation was observed in 9vHPV type prevalence in CIN1 (~50%) and CIN2/3 (81-85%). Types 31/33/45/52/58 accounted for 25-30% of CIN1 in Latin America and Europe, but 14-18% in North America and Asia. Types 31/33/45/52/58 accounted for 33-38% of CIN2/3 in Latin America (younger women), Europe, and Asia, but 17-18% of CIN2/3 in Latin America (older women) and North America. Non-vaccine HPV types 35/39/51/56/59 had similar or higher prevalence than qHPV types in CIN1 and were attributed to 2-11% of CIN2/3. Conclusions: The 9vHPV vaccine could potentially prevent the majority of CIN1-3, irrespective of geographic region. Notwithstanding, non-vaccine types 35/39/51/56/59 may still be responsible for some CIN1, and to a lesser extent CIN2/3.
KW - Adenocarcinoma in situ
KW - Cervical cancer
KW - Cervical intraepithelial neoplasia
KW - Human papillomavirus
UR - http://www.scopus.com/inward/record.url?scp=84961675401&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961675401&partnerID=8YFLogxK
U2 - 10.1016/j.pvr.2016.03.002
DO - 10.1016/j.pvr.2016.03.002
M3 - Article
C2 - 29074187
AN - SCOPUS:84961675401
VL - 2
SP - 61
EP - 69
JO - Papillomavirus Research
JF - Papillomavirus Research
SN - 2405-8521
ER -